Clinical pipeline under development (not yet declared for market)

Phase III clinical trial of trastuzumab injection is underway

Recombinant anti BCMA and CD3 bispecific antibody injection (HL16) phase I clinical trial is underway

The Phase I clinical trial of recombinant anti-PD-L1 and TGF - β dual function fusion protein injection (HL17) is underway

Recombinant anti-Claudin18.2 human monoclonal antibody has obtained clinical approval (HL15)

Pembrolizumab has obtained clinical approval (HL18)